Nordimet (Methotrexate)

Methotrexate, the active ingredient in Nordimet, is an antimetabolite presented as a subcutaneous injection for subcutaneous use. It is classified as a disease‑modifying antirheumatic drug (DMARD) and is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis and plaque psoriasis in adult patients. The medication is administered under medical supervision to achieve disease control.

GNH USA supplies Nordimet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including Europe, Asia and the Americas, and ensures quality‑controlled shipments, regulatory compliance and reliable logistics for global markets.

Nordimet (methotrexate) is a disease‑modifying antirheumatic drug that targets inflammatory pathways in autoimmune disorders.

- Rheumatoid arthritis: reduces joint inflammation, pain and swelling while slowing radiographic progression of joint damage. - Psoriatic arthritis: improves joint tenderness and swelling, reduces skin involvement, and helps prevent long‑term joint erosion. - Plaque psoriasis: decreases the extent and thickness of plaques, leading to clearer skin and reduced scaling.

Nordimet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Mouth ulcers (stomatitis) - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver toxicity or hepatic fibrosis - Bone marrow suppression leading to pancytopenia - Life‑threatening infections or pulmonary fibrosis

Prior to initiating Nordimet, several safety considerations should be reviewed.

- Pregnancy: contraindicated (Category X); avoid use in women who are pregnant or may become pregnant. - Renal impairment: assess kidney function; dose may need adjustment or avoidance in severe insufficiency. - Hepatic disease: monitor liver function tests regularly; discontinue if significant elevation occurs. - Infection risk: screen for active infections; postpone therapy during serious bacterial, viral or fungal infections. - Blood monitoring: perform baseline and periodic complete blood counts and liver panels to detect cytopenia or hepatotoxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate has a notable interaction profile that requires careful medication review.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (high‑dose NSAIDs): increase methotrexate toxicity. - Other folate antagonists (e.g., trimethoprim, pyrimethamine): additive bone‑marrow suppression. - Live vaccines: risk of severe infection due to immunosuppression. - Proton pump inhibitors (omeprazole) in high doses: may raise methotrexate levels. - Azathioprine or other immunosuppressants: heightened risk of infection and cytopenia.

Moderate Interactions (Monitor Closely): - Alcohol: potentiates liver toxicity. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Sulfonamide antibiotics: possible additive bone‑marrow effects. - Penicillins (high dose): may increase methotrexate concentrations. - Vitamin B12 or folic acid supplementation: may reduce efficacy, adjust dose accordingly.